Zemplar and Type 2 diabetes - a phase IV clinical study of FDA data

Summary:

Type 2 diabetes is reported as a side effect among people who take Zemplar (paricalcitol), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Toprol-Xl, and have Hyperparathyroidism secondary.

The phase IV clinical study analyzes which people have Type 2 diabetes when taking Zemplar. It is created by eHealthMe based on reports of 15,456 people who have side effects when taking Zemplar from the FDA, and is updated regularly.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.

What is Type 2 diabetes?

Type 2 diabetes is found to be associated with 1,433 drugs and 2,345 conditions by eHealthMe. Check the latest studies of Type 2 diabetes.

On Jul, 09, 2026

15,456 people reported to have side effects when taking Zemplar.
Among them, 14 people (0.09%) have Type 2 diabetes.

Among these 14 people:

How long have people been on Zemplar when they have Type 2 diabetes? *

What is the gender of people who have Type 2 diabetes when taking Zemplar? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Type 2 diabetes when taking Zemplar? *

What are other drugs people take besides Zemplar? *

What are other side effects people have besides Type 2 diabetes? *

Chronic Renal Failure (kidney failure): 8 people, 57.14%
Cardiac Failure Congestive: 7 people, 50.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 6 people, 42.86%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 28.57%
Pneumonia: 4 people, 28.57%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 28.57%
Loss Of Consciousness: 3 people, 21.43%
Hepatic Lesion: 3 people, 21.43%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 3 people, 21.43%
Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 3 people, 21.43%

What are the existing conditions these people have? *

Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 5 people, 35.71%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 2 people, 14.29%
Arrhythmias (irregular heartbeat): 2 people, 14.29%
Ischaemia (insufficient supply of blood to an organ, usually due to a blocked artery): 2 people, 14.29%
Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 14.29%
Sleep Disorder: 1 person, 7.14%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.14%
Apolipoprotein Abnormal: 1 person, 7.14%
Blood Parathyroid Hormone Increased: 1 person, 7.14%
Cardiac Disorder: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Zemplar and have Type 2 diabetes?

- Check whether Type 2 diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zemplar:

Zemplar (15,494 reports)

Type 2 diabetes treatments and more:

Type 2 diabetes (391,582 reports)

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type 2 diabetes:

Type 2 diabetes (1,433 drugs)

Browse all the conditions that are associated with Type 2 diabetes:

Type 2 diabetes (2,345 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Zemplar) and Zemplar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.